Orbimed Advisors LLC Buys Shares of 94,559 Insmed Incorporated (NASDAQ:INSM)

Orbimed Advisors LLC acquired a new stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 94,559 shares of the biopharmaceutical company's stock, valued at approximately $6,528,000. Orbimed Advisors LLC owned approximately 0.05% of Insmed as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Insmed by 10.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 105,313 shares of the biopharmaceutical company's stock valued at $7,270,000 after acquiring an additional 10,352 shares in the last quarter. Ensign Peak Advisors Inc lifted its stake in shares of Insmed by 9.3% during the 4th quarter. Ensign Peak Advisors Inc now owns 529,049 shares of the biopharmaceutical company's stock worth $36,526,000 after purchasing an additional 44,928 shares during the last quarter. Deutsche Bank AG boosted its position in Insmed by 76.6% during the fourth quarter. Deutsche Bank AG now owns 488,966 shares of the biopharmaceutical company's stock valued at $33,758,000 after purchasing an additional 212,024 shares in the last quarter. Driehaus Capital Management LLC boosted its position in Insmed by 2.3% during the fourth quarter. Driehaus Capital Management LLC now owns 171,289 shares of the biopharmaceutical company's stock valued at $11,826,000 after purchasing an additional 3,859 shares in the last quarter. Finally, Duquesne Family Office LLC grew its stake in Insmed by 2,867.4% in the fourth quarter. Duquesne Family Office LLC now owns 593,470 shares of the biopharmaceutical company's stock valued at $40,973,000 after purchasing an additional 573,470 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have commented on INSM. HC Wainwright reissued a "buy" rating and set a $90.00 price target on shares of Insmed in a research report on Monday. Stifel Nicolaus cut their target price on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research report on Friday, February 21st. Morgan Stanley raised their target price on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Guggenheim reiterated a "buy" rating and set a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. Finally, Bank of America raised their price objective on Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research note on Thursday, March 20th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $93.93.

Insiders Place Their Bets

In other news, CFO Sara Bonstein sold 18,322 shares of Insmed stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total value of $1,471,439.82. Following the sale, the chief financial officer now owns 118,863 shares in the company, valued at $9,545,887.53. This trade represents a 13.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO William Lewis sold 18,750 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $77.79, for a total transaction of $1,458,562.50. Following the transaction, the chief executive officer now owns 334,186 shares of the company's stock, valued at approximately $25,996,328.94. This trade represents a 5.31% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 88,232 shares of company stock worth $6,868,473. Company insiders own 3.00% of the company's stock.

Insmed Trading Up 4.1%

Shares of Insmed stock opened at $67.75 on Tuesday. The firm has a 50-day simple moving average of $72.17 and a two-hundred day simple moving average of $73.26. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The company has a market cap of $12.32 billion, a P/E ratio of -12.12 and a beta of 0.84.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.06) EPS. As a group, equities analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.